Abstract:Cryptosporidium parvum is a highly prevalent zoonotic and anthroponotic protozoan parasite that causes a diarrheal syndrome in children and neonatal livestock, culminating in growth retardation and mortalities. Despite the high prevalence of C. parvum, there are no fully effective and safe drugs for treating infections, and there is no vaccine. We have previously reported that the bacterial-like C. parvum lactate dehydrogenase (CpLDH) enzyme is essential for survival, virulence and growth of C. parvum in vitro and in vivo. In the present study, we screened compound libraries and identified inhibitors against the enzymatic activity of recombinant CpLDH protein in vitro. We tested the inhibitors for anti-Cryptosporidium effect using in vitro infection assays of HCT-8 cells monolayers and identified compounds NSC158011 and NSC10447 that inhibited the proliferation of intracellular C. parvum in vitro, with IC50 values of 14.88 and 72.65 μM, respectively. At doses tolerable in mice, we found that both NSC158011 and NSC10447 consistently significantly reduced the shedding of C. parvum oocysts in infected immunocompromised mice's feces, and prevented intestinal villous atrophy as well as mucosal erosion due to C. parvum. Together, our findings have unveiled promising anti-Cryptosporidium drug candidates that can be explored further for the development of the much needed novel therapeutic agents against C. parvum infections.Cryptosporidium parvum is a protozoan parasite that can cause a life-threatening gastrointestinal disease in children and in immunocompromised adults. The only approved drug for treatment of Cryptosporidium infections in humans is nitazoxanide, but it is not effective in immunocompromised individuals or in children with malnutrition. C. parvum possesses a unique lactate dehydrogenase (CpLDH) enzyme that it uses for generating metabolic energy (ATP) via the glycolytic pathway to fuel its growth and proliferation in the host. We have identified novel inhibitors for the enzymatic activity of CpLDH. Further, we have demonstrated that two of the CpLDH inhibitors effectively block the growth, proliferation and pathogenicity of C. parvum at tolerable doses in immunocompromised mice. Together, our findings have unveiled novel CpLDH inhibitors that can be explored for the development of efficacious therapeutic drugs against C. parvum infections.

Immunity Characteristics of Surface Adhesion Protein CP21 on Sporozoites and Oocysts of Cryptosporidium Parvum

Cryptosporidium Parvum: Identification of a New Surface Adhesion Protein on Sporozoite and Oocyst by Screening of a Phage-Display Cdna Library.

Prokaryotic Expression and Identification of Surface Adhesion Protein CP21 of Cry Ptos Poridium Parvum

Induction of immune responses in mice by a DNA vaccine encoding Cryptosporidium parvum Cp12 and Cp21 and its effect against homologous oocyst challenge.

Expression of the Recombinant Fusion Protein Cp15-23 of Cryptosporidium Parvum and Its Protective Test

Selection and Identification of a New Adhesion Protein of Cryptosporidium Parvum from a Cdna Library by Ribosome Display.

The Humoral and Cellular Immune Responses in Mice Induced by DNA Vaccine Expressing the Sporozoite Surface Protein of Cryptosporidium Parvum.

Construction of Eukaryotic Expression Vector of Cryptosporidium Parvum Cp16 Gene and Its Immunoprotective Effect

Amelioration of Cryptosporidium parvum infection in vitro and in vivo by targeting parasite fatty acyl-coenzyme A synthetases.

Preparation and Identification of Monoclonal Antibodies Against CP15/60 of Cryptosporidium Mouse Genotype

Efficacy of a Potential DNA Vaccine Encoding Cryptosporidium Baileyi Rhomboid Protein Against Homologous Challenge in Chickens

Humoral and cellular immune responses in the mice induced with DNA vaccines of sporozoites surface protein of Cryptosporidium parvum

A Novel Detection Method of Infection in Cattle Based on 1

[Serological Detection of Cryptosporidium Spp. Infection in Outpatients in Changchun].

Cloning and prokaryotic expression of the truncate oocyst wall protein of Cryptosporidium andersoni

Novel lactate dehydrogenase inhibitors with in vivo efficacy against Cryptosporidium parvum

A Single-Pass Type I Membrane Protein from the Apicomplexan Parasite Cryptosporidium Parvum with Nanomolar Binding Affinity to Host Cell Surface

Cloning,expression and immunologic analysis of the oocyst wall protein of Cryptosporidium andersoni

Comparative Characterization of CpCDPK1 and CpCDPK9, Two Potential Drug Targets Against Cryptosporidiosis

Characterization of Three Calcium-Dependent Protein Kinases of Cryptosporidium parvum

Comparative efficacy and safety of anti-cryptosporidial agents: an in vitro study on nitazoxanide, halofuginone lactate, KDU731, and paromomycin against Cryptosporidium parvum